Antiangiogenic effect of sulindac sulfide could be secondary to induction of apoptosis and cell cycle arrest

Anticancer Research

Volumn 26, Issue 4 B, 2006, Pages 3033-3041

  Flis, S ^a   Soltysiak Pawluczuk, D ^a   Jedrych, A ^a   Jastrzebski, Z ^a   Remiszewska, M ^a   Splawinski, Jacek ^a  

^a NATIONAL MEDICINES INSTITUTE   (Poland)

Author keywords

Angiogenesis; Apoptosis; Arachidonic acid (AA); Celecoxib; Cell cycle; Cyclooxygenase (COX); Human endothelial cells; Non steroidal anti inflammatory drugs (NSAIDs); Prostaglandin E2 (PGE2); Sulindac sulfide

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; ARACHIDONIC ACID; CASPASE 3; CASPASE 8; CELECOXIB; CELL PROTEIN; INDOMETACIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROTEIN BAX; SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE;

ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; ARACHIDONIC ACID; BALB 3T3 CELLS; CELL CYCLE; CELL LINE; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; ENDOTHELIAL CELLS; HUMANS; MICE; PYRAZOLES; SULFONAMIDES; SULINDAC;

EID: 33746679829     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Bossi P, Viale G, Lee AK, Alfano R, Coggi G and Bosari S: Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res 55: 5049-5053, 1995.
2. Aotake T, Lu CD, Chiba Y, Muraoka R and Tanigawa N: Changes of angiogenesis and tumor cell apoptosis during colorectal carcinogenesis. Clin Cancer Res 51: 5135-5142, 1999.
3. Choi HJ, Hyun MS, Jung GJ, Kim SS and Hong SH: Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. Oncology 55: 575-581, 1998.
4. Takebayashi Y, Aklyama S, Yamada K, Akiba S and Aikou T: Angiogenesis as unfavorable prognostic factor in human colorectal carcinoma. Cancer 78: 226-231, 1996.
5. Hurwitz HI, Fehrenbacher L, Norotny W, Cartwight T, Hainsworth J, Herin W, Berlin J, Baron A, Griffing I, Holmhreen E, Ferrara N, Fyle G, Rogers B, Ress R and Kabbinavat F: Bevacuzimab plus irinotecan, fluorouracil and leucovorin for metastatic colon cancer. N Engl J Med 350: 2335-2342, 2004.
6. Gwyn K and Sinicrope FA: Chemoprevention of colorectal cancer. Gastroenterology 97: 13-21, 2002.
7. Skopinska-Rozewska E, Piazza GA, Sommer E, Pamukcu R, Barcz E, Filewska M, Kupis W, Caban R, Rudzinski P, Bogdan J, Mlekodaj S and Sikorska E: Inhibition of angiogenesis by sulindac and its sulindac sulfone metabolite (FGN-1): a potential mechanism for their antineoplastic properties. In J Tissue React 20: 85-89, 1998.
8. Elwich-Flis S, Pawluczuk-Soltysiak D and Splawinski J: Anti-angiogenic and apoptotic effects of metabolites of sulindac on chick embryo chorioallantoic membrane (CAM). Hybrid Hybridomics 22: 55-60, 2003
9. Splawinski J, Malinga K, Konturek S, Klysik J and Michna M: The effect of age of embryo on the sensitivity of the chick chorioallantoic membrane to factors affecting angiogenesis. In: Mechanisms of Peptic Ulcer Healing. Halter F, Garner A, Tytgat GNJ (eds.). Falk Symposium. Academic Medical Centre. Amsterdam, The Netherlands, pp. 21-25, 1989
10. Niederburger E, Manderscheid C, Grosch S, Schmidt H, Ehnert C and Geisslinger G: Effects of selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol 68: 341-350, 2004
11. 2 and prostaglandin F2α on the longitudinal stomach strip of the rat. J Pharmacol Exp Ther 187: 501-510, 1973.
12. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS and Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug resistant cancer. Cancer Res 60: 1878-1886, 2000.
13. Miller KD Sweeney CJ and Sledge GW Jr: Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19: 1195-1206, 2001.
14. Granville DJ, Shaw JR, Leong S, Carthy ChM, Margaron PH, Hunt DW and McManus BM: Release of cytochrome c, Bax migration, Bit cleavage, and activation of caspase 2, 3, 6, 7, 8. and 9 during endothelial cell apoptosis. Am J Pathol 155: 1021-1024, 1999
15. Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, Pamukcu R and Ahnen DJ: Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 57: 1582-1584, 1997